Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Curr Opin Mol Ther. 2006 Apr;8(2):156-63.

    HuCNS-SC (StemCells).

    Source

    National Neuroscience Institute, National University of Singapore, 11 Jalan Tan Tock Seng, Singapore. obgpjt@nus.edu.sg

    Abstract

    HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 U.S. Food and Drug Administration approval of StemCells' investigational new drug application.

    PMID:
    16610769
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk